Hormone receptor (HR)-positive and HER2-negative (HR+/HER2-) metastatic/advanced breast cancer (mBC) is a major public health issue. During the last decades, a therapeutic challenge was to overcome the tumor's resistance to endocrine therapy (ET). Thanks to a better understanding of the molecular mechanisms of this resistance, effective new treatments have been developed, such as Kisqali® (ribociclib), a molecularly targeted therapy. This treatment blocks the growth and division of cancer cells by blocking proteins called CDK4/6 located inside the cell. This treatment, taken in combination with ET, blocks the harmful effect of hormones (estrogen) on cancer cell proliferation, and represent the standard first-line treatment of patients with HR+/HER2- mBC. But, as with any treatment, it is expected that some patients will have a good response and their disease will be stabilized or even in remission, while other patients will not benefit from treatment and will relapse. In order to make progress, it is necessary to identify pre-therapeutic markers predictive of response to this treatment and the molecular mechanisms of this resistance set up by the tumor before or under the effect of the treatment. The Trans-RosaLEE study aims to fill this gap by providing high-throughput molecular profiling (DNA and RNA) of a collection of tumor and blood samples from patients with RH+/HER2- mBC scheduled to start treatment with Kisqali® + ET. Samples will be collected just prior to initiation of therapy (pre-therapy) and just after discontinuation of therapy in the event of disease progression (post-therapy). The main objectives of the TransRosaLEE study are : * to determine if Kisqali® + ET treatment causes changes in the DNA and/or RNA genes of tumor; * to identify whether there is a molecular signature that would predict clinical outcome of patients treated with Kisqali® + ET (tumor response, survival); * to identify alterations in tumor's genes that could be targeted by a specific treatment and that would allow, in case of progression of the disease, to set up a new adapted treatment. The TransRosaLEE study is a collaborative study between the Paoli-Calmettes Institute (France, Marseille) and the pharmaceutical group Novartis. It will take place in up to 90 healthcare institutions in France, and 241 patients will be enrolled. It is closely linked to the non-interventional study RosaLEE promoted by Novartis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
115
Pre-treatment fragments will be collected during the biopsy visit organised as part of routine medical practice, prior to the start of treatment with ribociclib + ET
Post-treatment fragments will be collected during a biopsy visit specifically planned for Trans-RosaLEE study.
Sampling of 4 EDTA Tubes (4ml) and 2 Streck tubes (10ml)
Sampling of 2 Streck tubes (10ml)
Institut Paoli Calmettes
Marseille, France
Molecular alterations post- versus pre-treatment
Occurrence of molecular alterations, including DNA copy number, gene mutations by WES and messenger RNA (mRNA) expression profiles by RNA-seq in paired post- versus pre-treatment samples.
Time frame: At the date of first documented progression, assessed up to 54 months
Molecular alterations associated with progression free survival
Occurrence of molecular alterations in pre-treatment samples, such as DNA copy number alterations and mutational profiles analysed by WES, and mRNA expression profiles analysed by RNA-seq, associated with progression free survival.
Time frame: At 3 years after treatment initiation (Ribociclib+hormone therapy)
Molecular alterations pre and post-treatment
Occurrence of molecular alterations, including DNA copy number, gene mutations by WES and mRNA expression profiles by RNA-seq in the totality of pre- and post-treatment samples (paired and unpaired).
Time frame: At the date of first documented progression, assessed up to 54 months
Pre treatment molecular alterations associated with tumor response
Occurrence of molecular alterations in pre-treatment samples, such as DNA copy number alterations and mutational profiles analysed by WES and mRNA expression profiles analysed by RNA-seq, associated with tumour response according to RECIST 1.1 guidelines (complete and partial responses).
Time frame: At 3 years after treatment initiation (Ribociclib+hormone therapy)
Molecular alterations therapeutically actionable
Occurrence of molecular alterations in pre- and post-treatment samples, such as DNA copy number alterations and mutational profiles analysed by WES, which are therapeutically actionable according to the ESCAT scale.
Time frame: At the date of first documented progression, assessed up to 54 months
Percentage of patients with molecular alterations therapeutically actionable
Percentage of patients with molecular alterations such as DNA mutations and/or copy number alterations by WES, which are therapeutically actionable according to the ESCAT scale, in pre- and post-treatment samples.
Time frame: Through study completion, an average of 54 months
Percentage of patients with modification of the therapeutic strategy derived from the molecular profiling
Percentage of patients for which modification of the therapeutic strategy could have been derived from the molecular profiling of the post-treatment samples compared to that of the pre-treatment samples, according to the ESCAT scale.
Time frame: Through study completion, an average of 54 months
IHC profile ER
IHC profile ER of pre- and post-treatment samples.
Time frame: At the date of first documented progression, assessed up to 54 months
IHC profile PgR
IHC profile PgR of pre- and post-treatment samples.
Time frame: At the date of first documented progression, assessed up to 54 months
IHC profile HER2
IHC profile HER2 of pre- and post-treatment samples.
Time frame: At the date of first documented progression, assessed up to 54 months
Molecular subtypes PAM50
Molecular subtypes PAM50 of pre- and post-treatment samples.
Time frame: At the date of first documented progression, assessed up to 54 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.